11.   It allows generic companies to have their versions of brand-name drugs approved in advance so they can go to the market the day a patent expires.

12.   Ivax CFO Pfenniger said other generic companies are experiencing similar pricing problems.

13.   Martin Machovsky of Issues Dynamics helped create the Generic Drug Equity Coalition, a grouping of generic companies and consumer organizations.

14.   Other generic companies have made similar commitments, Nixon said.

15.   Relations are no more cordial among the generic companies themselves.

16.   That could provide an opening for the generic companies.

17.   The company argues that the three generic companies are planning versions of Zantac that should be excluded because they would violate the second patent.

18.   The biotech industry has questioned whether a generic company can develop equivalent protein-based drugs, citing the manufacturing complexity.

19.   The cost of such overhead is often much higher than at generic companies, industry experts say.

20.   The company is facing antitrust lawsuits by generic companies that may prove to be costly.